Background: Disease-modifying antirheumatic drugs (DMARDs) and new biologicals have improved the prognosis of systemic autoimmune diseases (SAD), but reciprocally increase the risk of recurrent respiratory tract (RRTI) and urinary tract (RUTI) infections. Given the rising of antibiotic resistance, the search for new strategies for the prevention of recurrent infections is a priority. Objectives: The purpose of this study was to evaluate the clinical benefit of the sublingual polybacterial vaccines on infections' rates in SAD patients. Methods: A retrospective observational study on a cohort of SAD patients on active inmunosuppression with RRTI and RUTI was conducted. Patients were treated with multibacterial sublingual vaccine formulations either for RRTI (Staphylococcus spp., S. pneumoniae, K. pneumoniae, M. catarrhalis, H. influenzae) 3 or/and RUTI (K. pneumoniae, E. coli, E. faecalis, P. vulgaris) 4 (Bactek/Uromune ® , Inmunotek SL Madrid, Spain) for 3-months period and clinical follow-up at 6-and 12-months. We monitored the frequency of infections, the intensity and severity of infections during follow-up. Immunological evaluation was performed, including: Serum immunoglobulin levels, IgG subclasses, specific antibodies' production: anti-pneumococcal, anti-Typhi polysaccharide and anti-tetanus toxoid antibodies, and B and T cell phenotype. Results: A total of 50 patients were evaluated, and 34 were eligible at 12-months.The mean age of the patients was 58±13 years, 31 women (91.17%) and 3 men (8.82%), 44.11% (n=15) with rheumatoid arthritis (RA), 23.52% (n=8) with systemic lupus erythematosus (SLE), 8.82% (n=3) mixed connective tissue disease, 2.94% (n=1) ankylosing spondylitis, 2.94% ( n=1) sacroileitis, 2,94% (n=1) psoriatic arthritis, 2,94% (n=1) SLE/RA, 2.94% (n=1) discoid LE/Sjögren, 2.94% (n=1) adult onset Still disease, 2,94% (n=1) sarcoidosis, 2.94% (n=1) SLElike. All patients showed a significant decrease in RRTI (3.15±2.66 vs 0.46±1.07, p<0.01) and RUTI (1.85±2.49 vs 0.35±1.06, p<0.01) frequency and use of antibiotics at 6-months of vaccine, except one with sarcoidosis. 23 of 34 patients (67.64%) disclosed defects on specific antibody production to polysaccharide and protein immunization. Three patients with antibody production deficit and pneumonia required prophylactic intravenous Ig. No adverse effects or SAD relapses were noted during the 1-year observational period. Conclusions: Mucosal vaccination in immunosuppressed patients due to SAD with recurrent infections resulted in lower rates of RRTIs and RUTIs with subsequent improvement in their quality of life. Our preliminary results need to be validated in controlled trials.
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or/and RUTI (K. pneumoniae, E. coli, E. faecalis, P. vulgaris) 4 (Bactek/Uromune ® , Inmunotek SL Madrid, Spain) for 3-months period and clinical follow-up at 6-and 12-months. We monitored the frequency of infections, the intensity and severity of infections during follow-up. Immunological evaluation was performed, including: Serum immunoglobulin levels, IgG subclasses, specific antibodies' production: anti-pneumococcal, anti-Typhi polysaccharide and anti-tetanus toxoid antibodies, and B and T cell phenotype. Results: A total of 50 patients were evaluated, and 34 were eligible at 12-months.The mean age of the patients was 58±13 years, 31 women (91.17%) and 3 men (8.82%), 44.11% (n=15) with rheumatoid arthritis (RA), 23.52% (n=8) with systemic lupus erythematosus (SLE), 8.82% (n=3) mixed connective tissue disease, 2.94% (n=1) ankylosing spondylitis, 2.94% ( n=1) sacroileitis, 2,94% (n=1) psoriatic arthritis, 2,94% (n=1) SLE/RA, 2.94% (n=1) discoid LE/Sjögren, 2.94% (n=1) adult onset Still disease, 2,94% (n=1) sarcoidosis, 2.94% (n=1) SLElike. All patients showed a significant decrease in RRTI (3.15±2.66 vs 0.46±1.07, p<0.01) and RUTI (1.85±2.49 vs 0.35±1.06, p<0.01) frequency and use of antibiotics at 6-months of vaccine, except one with sarcoidosis. 23 of 34 patients (67.64%) disclosed defects on specific antibody production to polysaccharide and protein immunization. Three patients with antibody production deficit and pneumonia required prophylactic intravenous Ig. No adverse effects or SAD relapses were noted during the 1-year observational period. Background: Intraarticular (IA) procedures have both diagnostic and therapeutic purposes in patients with arthritis. The therapeutic benefit of IA glucocorticoids (GC) injection in patients with rheumatologic diseases is well described. However, IA procedures are associated with increased risk of Septic arthritis (SA). Rapid diagnose and correct treatment is crucial to avoid joint damage, sepsis and potential fatal outcome. However, patients in risk of evolving SA secondarily to GC injection or arthrocentesis are not well defined. Objectives: The aim of this study was to evaluate the risk of SA in patients who received an IA GC injection or an isolated joint puncture, and to describe possible characteristics for these patients. Methods: All patients' undergoing IA procedures at the orthopaedic and rheumatological departments of Fuhnen from January 2006 to December 2013 were identified in the central database and included by register extraction. Patients who developed SA within 30 days after IA GC injection were registered as cases. SA was defined as clinically inflamed joint and positive synovial fluid culture. Retrospectively, data on age, gender, affected joint location, bacterial agent, pre-existing inflammatory disorder and death within 30 days were extracted from the patient files. According to local recommendations a non-touch sterile technic where used for IA procedures. Patients were informed about the risk for SA and motivated to seek medical attention if suspicion of infection or lack of improvement.
Results: 22370 IA procedures were registered; 14118 IA GC injections and 8252 arthrocentesis. Eleven patients with SA were registered. Eleven patients developed SA subsequently to IA GC injection (0.08% of all GC injections). For patients' demography, joint distribution, bacterial agent and pre-excisting joint disease ( 
